Evidence map›Paper›PMID 24887090›Full record

ArticleJournal of experimental & clinical cancer research : CR2014

Restoration of E-cadherin expression by selective Cox-2 inhibition and the clinical relevance of the epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma.

Ryoichi Fujii, Yorihisa Imanishi, Katsushi Shibata, Nobuya Sakai, Koji Sakamoto, Seiji Shigetomi, Noboru Habu, Kuninori Otsuka, Yoichiro Sato, Yoshihiro Watanabe and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Role of Cyclooxygenase-2 in Head and Neck Tumorigenesis.International journal of molecular sciences · 2020
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. 4,5-Diaryl 3(Molecules (Basel, Switzerland) · 2019
    Article
  19. Ethanol extracts ofFood & nutrition research · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Ryoichi Fujii
Yorihisa ImanishiDepartment of Otorhinolaryngology-Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, Japan. yorihisa@ja2.so-net.ne.jp.
Katsushi Shibata
Nobuya Sakai
Koji Sakamoto
Seiji Shigetomi
Noboru Habu
Kuninori Otsuka
Yoichiro Sato
Yoshihiro Watanabe
Hiroyuki Ozawa
Toshiki Tomita
Kaori Kameyama
Masato Fujii
Kaoru Ogawa
Keio University · JPHimeji Dokkyo University · JPKawasaki Municipal Hospital · JPkeiyu Hospital · JPSaiseikai Utsunomiya hospital · JPTokyo Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe epithelial-to-mesenchymal transition (EMT) accompanied by the downregulation of E-cadherin has been thought to promote metastasis. Cyclooxygenase-2 (Cox-2) is presumed to contribute to cancer progression through its multifaceted function, and recently its inverse relationship with E-cadherin was suggested. The aim of the present study was to investigate whether selective Cox-2 inhibitors restore the expression of E-cadherin in head and neck squamous cell carcinoma (HNSCC) cells, and to examine the possible correlations of the expression levels of EMT-related molecules with clinicopathological factors in HNSCC.

methodsWe used quantitative real-time PCR to examine the effects of three selective Cox-2 inhibitors, i.e., celecoxib, NS-398, and SC-791 on the gene expressions of E-cadherin (CDH-1) and its transcriptional repressors (SIP1, Snail, Twist) in the human HNSCC cell lines HSC-2 and HSC-4. To evaluate the changes in E-cadherin expression on the cell surface, we used a flowcytometer and immunofluorescent staining in addition to Western blotting. We evaluated and statistically analyzed the clinicopathological factors and mRNA expressions of Cox-2, CDH-1 and its repressors in surgical specimens of 40 patients with tongue squamous cell carcinoma (TSCC).

resultsThe selective Cox-2 inhibitors upregulated the E-cadherin expression on the cell surface of the HNSCC cells through the downregulation of its transcriptional repressors. The extent of this effect depended on the baseline expression levels of both E-cadherin and Cox-2 in each cell line. A univariate analysis showed that higher Cox-2 mRNA expression (p = 0.037), lower CDH-1 mRNA expression (p = 0.020), and advanced T-classification (p = 0.036) were significantly correlated with lymph node metastasis in TSCC. A multivariate logistic regression revealed that lower CDH-1 mRNA expression was the independent risk factor affecting lymph node metastasis (p = 0.041).

conclusionsThese findings suggest that the appropriately selective administration of certain Cox-2 inhibitors may have an anti-metastatic effect through suppression of the EMT by restoring E-cadherin expression. In addition, the downregulation of CDH-1 resulting from the EMT may be closely involved in lymph node metastasis in TSCC.

Indexed as

Epithelial-Mesenchymal TransitionAntigens, CDAntineoplastic AgentsCadherinsCarcinoma, Squamous CellCell Line, TumorCyclooxygenase 2Cyclooxygenase 2 InhibitorsDrug Screening Assays, AntitumorFemaleGene ExpressionGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMaleMiddle AgedAntigens, CDAntineoplastic AgentsCadherinsCDH1 protein, humanCyclooxygenase 2Cyclooxygenase 2 InhibitorsN-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamideNitrobenzenesPTGS2 protein, humanRNA, MessengerSulfonamides

Identifiers

PMID24887090
PMCPMC4030015
OpenAlexW2119724079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.